Compare IDEXX Laboratories, Inc. (IDXX) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs PepsiCo, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $551.97 (market cap $44.48B), while PepsiCo, Inc. trades at $134.56 (market cap $184.89B). The key difference: PepsiCo, Inc. is far larger — about 4.2× IDEXX Laboratories, Inc.'s market cap, and PepsiCo, Inc. pays a 4.37% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PEP | |
|---|---|---|
Market Cap | $44.48B | $184.89B |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $170.44 |
52-Week Low | $520.87 | $135.40 |
Enterprise Value | $45.38B | $227.39B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
PepsiCo (PEP) trades at $134.62, down 1.82% over the past day, with a bearish technical signal from moving averages. The company reported revenue of $93.93B in 2025, with a net income margin of 10.78% and a P/E ratio of 17.75. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while Q3 2026 earnings are anticipated at $2.32 EPS. Analyst consensus is a 'Hold' with a $158.50 price target, suggesting moderate upside from current levels.
The outlook for PEP hinges on execution of its North American turnaround and margin expansion initiatives. Risks include competitive pressures and sensitivity to consumer spending. With strong cash flow generation and a dividend yield near 4%, the stock offers value for income-focused investors, though near-term volatility may persist amid earnings uncertainty and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
